Capital and Coast District Health Board logo

ALS-8176-503

A Study of ALS-008176 in Infants Hospitalized With RSV

This study is currently recruiting participants.

Phone: Marina Dzhelali on 04 918 5117

Email: Marina.Dzhelali@ccdhb.org.nz 

Trial website:https://clinicaltrials.gov/ct2/show/NCT02202356

Trial purpose: This study will assess the safety, tolerability, pharmacokinetics (PK) and anti-viral effect of single and multiple doses of ALS-008176 in infants hospitalized with respiratory syncytial virus (RSV).

MEDI8897

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. (MEDI8897 Ph2b)

This study is not currently recruiting participants.

Phone: Marina Dzhelali on 04 918 5117

Email: Marina.Dzhelali@ccdhb.org.nz

Trial website: https://clinicaltrials.gov/ct2/show/NCT02878330

Trial purpose: The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy preterm infants who are between 29 and 35 weeks gestational age and entering their first RSV season.

RSV F Vaccine

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

This study is currently recruiting participants (the recruitment window has closed for the year but we will be recruiting in following years).

Phone: Marina Dzhelali on 04 918 5117

Email: Marina.Dzhelali@ccdhb.org.nz

Trial website: https://clinicaltrials.gov/ct2/show/NCT02624947

Trial purpose: The purpose of this study is to determine the efficacy of maternal immunization with the RSV F vaccine against symptomatic RSV lower respiratory tract infection (LRTI) with hypoxemia through the first 90 days of life in infants.

 

 

Last updated 26 September 2017.